Background: Fulminant liver failure is attribute to (infective or sterile) inflammation response or hyponatremia and cause pos-transplant mortality and morbidities. Contineous renal replacement therapy (CRRT) can effectively remove the inflammation mediators and maintain inner environment steady . Objective: To valuate early CRRT in liver transplant recipients with previous hepatic encephalopathy.  Method: A total of 82 liver grafts from Donors of Cardiac Deceased(DCD) were transplanted to fulminant liver failure recipients from December 2012 to May 2017. CRRT(continuous veno-venous hemofiltration) were initiated in the first 24~48 hours after transplantation and extended 3~5 days in 44 patients regardless of renal dysfunction; while 38 patients were regularly treated after operation(control group). Retrospectively reviewed the clinical variables and outcomes in 60 days after transplantation. Results: None of the enrolled patients developed any CRRT related severe complications. Renal function did not differ between two group(P=0.22). There are significant differences of blood ammonia reduction(mean62.2% vs 31.2%,P=0.002), SIRS score reduction(mean0.9 vs -0.1,p=0.007 ) and lactic acid clearance rate(median 74% vs 55%,p=0.036) between early CRRT and control groups. Patients treated as early CRRT has a shorter length of ICU stay( median3.6 vs 7.9days,p=0.032), consciousness retrieving time(median10.2vs26.0hours,p=0.001) and 28 day ventilation-free days(mean 25.2vs20days,p=0.019). Although there is no difference of re-intubation and acute renal dysfunction incidence, early CRRT group got less pulmonary infections (58.5%vs86.8%,p=0.023).The overall mortality did not change significantly whether early CRRT or not.(90.2%vs78.9%,p=0.096). Conclusion: Early continuous renal replacement therapy after liver transplantation for recipients due to fulminant liver failure is probably safe and may improved clinical outcomes.